Equities Analysts Offer Predictions for ARQT FY2027 Earnings

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Investment analysts at HC Wainwright upped their FY2027 EPS estimates for Arcutis Biotherapeutics in a research report issued to clients and investors on Wednesday, February 26th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $1.12 per share for the year, up from their previous forecast of $0.94. HC Wainwright currently has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ FY2028 earnings at $1.82 EPS.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.19. The firm had revenue of $71.36 million for the quarter, compared to analyst estimates of $60.52 million. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%.

Several other research analysts also recently weighed in on the stock. Guggenheim reissued a “buy” rating on shares of Arcutis Biotherapeutics in a research note on Monday. Needham & Company LLC reissued a “buy” rating and issued a $20.00 price objective on shares of Arcutis Biotherapeutics in a research report on Wednesday. Mizuho raised their target price on shares of Arcutis Biotherapeutics from $20.00 to $21.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, The Goldman Sachs Group raised their price objective on Arcutis Biotherapeutics from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Arcutis Biotherapeutics Stock Down 3.2 %

Shares of NASDAQ:ARQT opened at $12.80 on Friday. The company has a quick ratio of 2.38, a current ratio of 2.46 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $1.50 billion, a P/E ratio of -7.15 and a beta of 1.29. Arcutis Biotherapeutics has a 52-week low of $6.99 and a 52-week high of $16.20. The stock’s fifty day simple moving average is $13.56 and its 200-day simple moving average is $11.43.

Insider Transactions at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, Director Howard G. Welgus sold 10,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $12.71, for a total transaction of $127,100.00. Following the transaction, the director now owns 141,944 shares in the company, valued at $1,804,108.24. The trade was a 6.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Todd Franklin Watanabe sold 15,000 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $15.17, for a total value of $227,550.00. Following the completion of the sale, the insider now owns 823,430 shares of the company’s stock, valued at approximately $12,491,433.10. This trade represents a 1.79 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,029 shares of company stock worth $756,017 in the last three months. 9.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ARQT. Creative Planning purchased a new stake in shares of Arcutis Biotherapeutics during the third quarter valued at approximately $127,000. abrdn plc boosted its stake in shares of Arcutis Biotherapeutics by 223.8% in the third quarter. abrdn plc now owns 482,074 shares of the company’s stock valued at $4,483,000 after purchasing an additional 333,200 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Arcutis Biotherapeutics by 65.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,482 shares of the company’s stock valued at $209,000 after purchasing an additional 8,881 shares in the last quarter. GSA Capital Partners LLP increased its stake in Arcutis Biotherapeutics by 730.0% during the 3rd quarter. GSA Capital Partners LLP now owns 237,174 shares of the company’s stock worth $2,206,000 after buying an additional 208,599 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in Arcutis Biotherapeutics by 9.9% in the 3rd quarter. Victory Capital Management Inc. now owns 12,843 shares of the company’s stock worth $119,000 after buying an additional 1,155 shares in the last quarter.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.